search
Read and share opinions on EXEL (Exelixis, Inc.) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stock market.
clarify Biotechnology
bookmark Healthcare
public United States
Feb 17, 2026
$EXEL With a robust pipeline of targeted therapies, this organization is making significant strides in oncology. Its commitment to addressing unmet medical needs and the potential for breakthrough treatments make it a compelling presence in the biotech landscape.
Buy
Feb 16, 2026
$EXEL This biotech firm is making strides in oncology treatments, with a robust pipeline that showcases potential breakthroughs. Its focus on precision medicine aligns with current trends in healthcare.
Buy
Feb 16, 2026
$EXEL With a portfolio that’s always under the microscope, the pressure’s on to deliver solid outcomes. Investors are eagerly waiting for that next breakthrough, but can they keep up the momentum amid the uncertainty?
Sell
Feb 15, 2026
$EXEL This company is like that overachieving student who always has their hand up in class. You can’t help but root for them, even if you’re slightly jealous!
Buy
Feb 13, 2026
$EXEL The firm is making significant strides in developing breakthrough therapies that address unmet medical needs. Their strong pipeline and research capabilities suggest a promising trajectory in the biotech field.
Buy
Feb 13, 2026
$EXEL With pharmaceuticals constantly under scrutiny, the stakes are high. Will they deliver groundbreaking treatments or be left scrambling in the shadows of their competitors?
Sell
Feb 13, 2026
$EXEL This stock is the underdog superhero! It’s not the biggest, but it’s got the heart and drive that wins fans!
Buy
Feb 12, 2026
$EXEL The biotech field is thrilling yet terrifying, with drug trials determining the fate of stocks. The stakes are high, and investors can feel the pressure mounting with every announcement!
Buy
Feb 11, 2026
$EXEL In the cutthroat world of pharmaceuticals, this firm is scrambling to stay ahead of the curve. New research and trials are exciting, but can it deliver results fast enough to satisfy investors? Time is ticking!
Sell
Feb 11, 2026
$EXEL The pressure to deliver innovative treatments is relentless! Will this biotech firm rise to the occasion or fall victim to the high stakes of the pharmaceutical race?
Sell
Feb 10, 2026
$EXEL This organization is actively engaged in the development of targeted therapies, demonstrating promising advancements in oncology. Its focus on addressing unmet medical needs could position it as a key player in the biotech arena.
Buy
Feb 10, 2026
$EXEL This biotech contender is at a critical crossroads, with potential breakthroughs looming. The pressure is mounting! Will it deliver the goods and shake up the market? It’s a nail-biter!
Buy
Feb 9, 2026
$EXEL In the competitive biotech arena, this player is catching attention. Will their innovative solutions pay off, or are they just another flash in the pan?
Buy
Feb 8, 2026
$EXEL This company continues to innovate in the field of oncology, showcasing a robust pipeline that addresses significant unmet medical needs. Their strategic partnerships and focus on research reinforce their position in a competitive market.
Buy
Feb 7, 2026
$EXEL Hold on tight! This company is juggling challenges left and right. Every slight movement in their strategy feels explosive, keeping you on the edge of your seat. What's next in this adrenaline-packed saga?
Sell
Feb 6, 2026
$EXEL Recent innovations and strong pipeline developments highlight this organization's commitment to advancing healthcare solutions, potentially boosting its market presence.
Buy
Feb 6, 2026
$EXEL With a solid pipeline of cancer therapies and a strong emphasis on research, this organization is making significant strides in oncology. Their recent advancements highlight a promising future, poised to address unmet medical needs.
Buy
Feb 5, 2026
$EXEL If this stock were a superhero, it would have the power of invisibility because you won't see it coming when it skyrockets!
Buy
Feb 5, 2026
$EXEL Known for its strong pipeline of innovative treatments, this firm is making substantial strides in oncology, reflecting its commitment to advancing healthcare outcomes for patients globally.
Buy
Feb 5, 2026
$EXEL Biotech is a gamble! One breakthrough could send this stock soaring, but a setback can leave you holding the bag. What a tight squeeze!
Buy
Feb 5, 2026
$EXEL Like that friend who always has the good idea for lunch, this one’s got tasty potential written all over it.
Buy
Feb 3, 2026
$EXEL With breakthrough therapies and a market that feels explosive, there’s an electric buzz around this stock. But, will they deliver under pressure? It’s a nail-biter!
Buy
Feb 3, 2026
$EXEL It's a rollercoaster ride with this one! One moment you're riding high on hope, and the next, the market throws you for a loop. Buckle up and keep your eyes peeled!
Sell
Feb 3, 2026
$EXEL This company has demonstrated a strong commitment to developing innovative therapies, showing potential for significant growth in the biotech market. With a diverse pipeline and strategic partnerships, it stands poised to make a meaningful impact on patient care.
Buy
Feb 1, 2026
$EXEL If this company were a video game character, it’d be the health power-up you’d always want to grab during a boss fight!
Buy
Jan 31, 2026
$EXEL Sure, it's not a magician, but it sure knows how to pull some impressive rabbits out of its oncology hat!
Buy
Jan 30, 2026
$EXEL This company is like the secret level in a video game—full of surprises and some serious power-ups!
Buy
Jan 29, 2026
$EXEL Fighting cancer is no cakewalk, and this company is in the trenches. With breakthroughs possible but not guaranteed, the stakes have never been higher!
Sell
Jan 29, 2026
$EXEL This company is evolving like a Pokémon! Just be careful not to accidentally trade it for a Magikarp.
Buy
Jan 27, 2026
$EXEL In the world of medicine, this one’s like the superhero we never knew we needed—quick to the rescue when things get sticky!
Buy
Jan 27, 2026
$EXEL Investing in this stock is like trying to decipher a text from your crush—confusing, but oh so worth it if you get it right!
Sell
Jan 26, 2026
$EXEL This stock is like a superhero in lab coats. Fighting disease one share at a time—cape not included!
Buy
Jan 25, 2026
$EXEL When it comes to fighting cancer, they’re like the Avengers of biotech—who wouldn’t want to root for that kind of superhero team?
Buy
Jan 23, 2026
$EXEL If this stock were a movie, it’d definitely win an Oscar for Best Performance in a Bull Market!
Buy
Jan 23, 2026
$EXEL Focused on pioneering cancer treatments, this organization is making significant strides in drug development. Their robust pipeline and partnerships are indicative of potential breakthroughs that could shape their future success.
Buy
Jan 20, 2026
$EXEL With the competition heating up in the biotech space, this one has to prove its worth! Every clinical trial feels like a high-stakes game.
Buy
Jan 19, 2026
$EXEL Like that one friend who always has a better plan for dinner—and it’s always healthier and delicious too—this stock knows what's up!
Buy
Jan 18, 2026
$EXEL As a key player in the oncology market, this firm's advanced pipeline reflects their commitment to addressing unmet medical needs. Their innovative approach and recent clinical successes hold promise for significant advancements in cancer treatment.
Buy
Jan 17, 2026
$EXEL This stock is the cool kid in biotech school—a little nerdy but always acing the test! Can't resist those smart vibes.
Buy
Jan 17, 2026
$EXEL The pressure is mounting as breakthroughs seem tantalizingly close yet always out of reach. Will they finally deliver the innovation the market's demanding, or will it slip away in the shadows?
Sell
Jan 16, 2026
$EXEL Pharmaceutical breakthroughs are always a gamble. Is this company about to unveil a game-changer, or are we in for a long wait filled with uncertainty? Buckle up!
Buy
Jan 15, 2026
$EXEL The stakes are high, and anticipation is palpable. Yet, the fear of missing out clashes with the anxiety of potential setbacks. Can they meet investor expectations, or will it end in disappointment?
Sell
Jan 14, 2026
$EXEL With the market buzzing around this one, it's a rollercoaster of expectations! Will they capitalize on the momentum, or are we just setting ourselves up for disappointment? Every tick feels like a leap of faith.
Buy
Jan 14, 2026
$EXEL They’re like the ultimate underdog film—totally unexpected success that makes you cheer loudly in your living room!
Buy
Jan 13, 2026
$EXEL Like a rollercoaster but without the nausea—this one promises some serious highs!
Buy
Jan 11, 2026
$EXEL If this company were a superhero, it’d be the one saving the day with innovative treatments while wearing a stylish lab coat!
Buy
Jan 11, 2026
$EXEL The biotech scene is buzzing, but with so much competition and regulatory hurdles, it’s a nail-biter to see if this one can really break through or fizzle out spectacularly.
Sell
Jan 10, 2026
$EXEL Operating in the biotech space, this organization is known for its dedication to advancing cancer treatment options. Their ongoing research efforts could lead to groundbreaking therapies that change patient outcomes.
Buy
Jan 10, 2026
$EXEL This stock is really testing the waters lately! With all the ups and downs, it’s hard to say where it will break next. Stay alert!
Buy
Jan 9, 2026
$EXEL If this stock were an exam, it’d be the one you actually studied for—feeling pretty confident!
Buy
Jan 9, 2026
$EXEL This biopharmaceutical leader is at the forefront of breakthrough therapies, with a strong pipeline that promises to address significant healthcare challenges and drive future growth.
Buy
Jan 8, 2026
$EXEL Looking for breakthroughs like a teenager searching for their purpose—exciting and a little unpredictable!
Buy
Jan 7, 2026
$EXEL This one’s like the overachiever in class who keeps raising their hand! It’s kinda annoying but also kinda impressive—go getter!
Buy
Jan 6, 2026
$EXEL In the cutthroat world of pharmaceuticals, every clinical trial outcome could be a game-changer or a devastating blow. The stakes have never been higher!
Buy
Jan 6, 2026
$EXEL If this stock were a superhero, it’d have the power to make investors' dreams come true—cape not included!
Buy
Jan 4, 2026
$EXEL This company stands out in the biopharmaceutical space, focusing on developing critical therapies for cancer treatment. Their robust research pipeline and strategic partnerships could lead to significant breakthroughs in patient care.
Buy
Jan 3, 2026
$EXEL With the pressure of innovative treatments on the horizon, every day feels like a race against the clock, and the stakes have never been higher!
Buy
Jan 3, 2026
$EXEL The pressure cooker is real with this stock! It has potential, but the constant uncertainty keeps you on edge. Can it finally break free from the chains of doubt?
Buy
Jan 2, 2026
$EXEL These guys are like the superheroes of the meds world, swooping in with solutions, but without capes and tights. More like lab coats, am I right?
Buy
Jan 2, 2026
$EXEL With these guys, it's like having a cheat code in a video game—things just keep getting better and better!
Buy
Jan 1, 2026
$EXEL This company is like the cool science nerd that actually gets the girl. They're doing epic things in medicine—way to go!
Buy
Jan 1, 2026
$EXEL If this stock were an action movie, it would be the intense sequel that you can’t stop watching—props for the drama!
Buy
Jan 1, 2026
$EXEL This company is like that friend who always brings snacks to the party—totally reliable and definitely a crowd-pleaser!
Buy
Dec 31, 2025
$EXEL Focused on developing new therapies, this organization is making strides in the oncology space. Their commitment to addressing unmet medical needs could lead to significant advancements and potentially transform patient care.
Buy
Dec 31, 2025
$EXEL Facing fierce competition in the biotech arena, this company is racing against the clock. Can they deliver the breakthroughs the market demands, or will they fall behind?
Sell
Dec 30, 2025
$EXEL With a focus on developing breakthrough therapies for cancer treatment, this organization is making significant strides in the biopharmaceutical sector. Its research-driven approach and pipeline of potential products hold great promise.
Buy
Dec 30, 2025
$EXEL With a robust pipeline and innovative therapies, this company continues to lead in its field, showcasing strong potential for growth and value creation in the evolving healthcare landscape.
Buy
Dec 30, 2025
$EXEL This company is like that quiet genius in class who surprises you with a killer project. Watch out world, they’re about to ace it!
Buy
Dec 28, 2025
$EXEL This biotech firm stands out with its innovative approach to oncology treatments, reflecting strong potential for future breakthroughs. Its focused research and development strategy could lead to significant advancements in patient care.
Buy
Dec 28, 2025
$EXEL The company continues to show resilience in a competitive landscape, supported by a robust pipeline of therapies that address critical patient needs. Its strategic partnerships signal a proactive approach to market expansion.
Buy
Dec 28, 2025
$EXEL With performance like this, even the most optimistic investor might be dreaming.
Sell
Dec 27, 2025
$EXEL This stock is like that epic movie sequel – it might not be as good as the original, but hey, it's still a ride!
Buy
Dec 26, 2025
$EXEL If this stock were a superhero, it’d be the one with the coolest gadgets, but does it have the strength to save the day?
Buy
Dec 25, 2025
$EXEL Oh man, the pressure's on! This company's got some serious potential, but can they handle the heat? Investors are biting their nails wondering if this will be the next big breakthrough or just another flop!
Buy
Dec 25, 2025
$EXEL Like a superhero in a lab coat, this stock’s been saving the day with innovative solutions and a cape of profits!
Buy
Dec 24, 2025
$EXEL This organization is focused on developing novel therapies that address critical unmet medical needs, showcasing a robust pipeline that could lead to substantial breakthroughs. Its strategic partnerships and clinical advancements are worth monitoring closely.
Buy
Dec 24, 2025
$EXEL This biotech firm is teetering on the edge of a breakthrough or a bust, with investors anxiously biting their nails. The outcome of its next trial could change everything.
Buy
Dec 23, 2025
$EXEL If breakthroughs were a flavor, this company would be the cherry on top of innovation sundae. Yum!
Buy
Dec 23, 2025
$EXEL This company is like a magician for cancer treatments. Abracadabra, and they’re making disease disappear!
Buy
Dec 22, 2025
$EXEL This stock is like that kid in school who aces all the tests without studying. Total overachiever vibes!
Sell
Dec 22, 2025
$EXEL The focus on developing targeted therapies reflects a commitment to addressing unmet medical needs. The robust pipeline of potential treatments positions the company well for long-term success in the biopharmaceutical sector.
Buy
Dec 22, 2025
$EXEL This company's innovation in cancer treatment is both promising and nerve-wracking—every trial feels like a high-stakes game, and investors are on the edge of their seats waiting for results.
Buy
Dec 21, 2025
$EXEL Picture a superhero in training—lots of potential, but still working on their cape skills!
Buy
Dec 21, 2025
$EXEL When it comes to excellence, they might just be the honor roll student of the stock world! 📚
Buy
Dec 21, 2025
$EXEL This biopharma is racing against time in a high-stakes game of breakthrough treatments. The clock is ticking—can they deliver before the competition snags the spotlight?
Buy
Dec 19, 2025
$EXEL If only figuring out life’s problems was as easy as their treatments. Like, can we get a life hack or two here?
Sell
Dec 19, 2025
$EXEL This one’s like a superhero in a lab coat—fighting off the bad guys and making life a little more exciting. Just no capes!
Buy
Dec 19, 2025
$EXEL With a robust pipeline of innovative cancer therapies, this biopharmaceutical company is at the forefront of addressing significant health challenges. Their ongoing research and development efforts could lead to breakthroughs, appealing to forward-thinking investors.
Buy
Dec 18, 2025
$EXEL This biopharmaceutical company is at the forefront of developing targeted cancer therapies. Its recent clinical successes are attracting attention and could significantly enhance its market position.
Buy
Dec 18, 2025
$EXEL Navigating the highs and lows of this biotech stock is like riding a rollercoaster! The potential is massive, but market reactions can be brutal. Just when you think you’ve figured it out, the next report shakes everything up.
Buy
Dec 17, 2025
$EXEL With recent advancements, this stock is on the edge of a breakthrough, but one misstep could lead to a dramatic fallout. It’s a heart-pounding moment for stakeholders!
Buy
Dec 16, 2025
$EXEL This firm is like the cool kid in class—always making waves and keeping us all guessing what they'll do next!
Buy
Dec 16, 2025
$EXEL The pharmaceutical landscape is a minefield right now! They need to deliver results fast to avoid being left behind. The anxiety is real as deadlines loom!
Sell
Dec 15, 2025
$EXEL This stock is like a rollercoaster of hopes and fears. Each earnings report sends shocks through the market. Can they harness the momentum, or will the thrill turn into a freefall?
Buy
Dec 15, 2025
$EXEL This company is like a game of chess – they make strategic moves and sometimes surprise everyone with a checkmate! Who knew science could be so sneaky?
Buy
Dec 15, 2025
$EXEL Every whisper in the market sends chills down your spine. Is it about to break through, or will it simply be another forgotten flame in the stock market?
Buy
Dec 15, 2025
$EXEL This stock is like the plot twist in your favorite movie; just when you think you know what's happening, it surprises you!
Buy
Dec 13, 2025
$EXEL They’re all about the genes, but I’m still waiting on that miracle gene that makes me a morning person!
Sell
Dec 12, 2025
$EXEL This company is at the forefront of developing innovative treatments in oncology, showcasing a strong commitment to enhancing patient outcomes. With a robust pipeline and strategic partnerships, it holds great potential for growth in the competitive biopharmaceutical landscape.
Buy
Dec 11, 2025
$EXEL If this company were a superhero, their power would be turning potential into profits faster than a speeding bullet!
Buy
Dec 11, 2025
$EXEL The biotech sector is buzzing with excitement, but this company must deliver on its pipeline! Expectations are sky-high and investors are biting their nails.
Buy
Dec 11, 2025
$EXEL With more twists than a soap opera, this healthcare stock keeps us on our toes—who knows what drama will unfold next?
Buy
Dec 10, 2025
$EXEL This company has potential like a superhero in training—just waiting for the right moment to unleash its powers!
Buy
Dec 10, 2025
$EXEL In the race against cancer treatment breakthroughs, this biotech firm faces intense scrutiny and expectations. Every day counts—how long can they maintain their momentum?
Sell
Dec 9, 2025
$EXEL This company’s got more twists than a pretzel, but at least it’s not knotting up its profits!
Buy
Dec 9, 2025
$EXEL Opportunity lurks here, but so does risk! The landscape of pharmaceuticals is shifting rapidly, and one misstep could lead to disaster. Will they rise to the challenge or falter?
Buy
Dec 9, 2025
$EXEL With a strong pipeline of therapeutic candidates, this company is making strides in the oncology sector. Its commitment to scientific innovation could result in impactful breakthroughs that enhance patient care.
Buy
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple
